Glonghui May 13 丨 Shanghai Pharmaceutical (601607)(601607pokerstorenearme.SH) AnnouncementpokerstorenearmeThe company's independently developed "I031 Tablets" received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration. I031 is a small molecule inhibitor that can inhibit tumor proliferation. Preclinical studies have shown that I031 can inhibit tumor growth in animal models of human tumors. The project was independently developed by Shanghai Pharmaceutical, and the company has full intellectual property rights.
